Evidence map›Paper›PMID 23881453›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2013

Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury.

Selva Baltan, Richard S Morrison, Sean P Murphy

Open access · bronzeAbstract readReview
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. White matter injury in ischemic stroke.Progress in neurobiology · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Selva BaltanDepartment of Neurosciences, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH, 44195, USA, baltans@ccf.org.
Richard S Morrison
Sean P Murphy
Cleveland Clinic · USNeurological Surgery · USUniversity of Washington · US

Funding

Vulnerability of Aging White Matter to IschemiaR01AG033720 · NIA · UNIVERSITY OF WASHINGTON · PI BALTAN, SELVA · 2010 to 2021
$2.7M
Histone deacetylases - therapeutic targets for functional restoration after strokR01NS065319 · NINDS · UNIVERSITY OF WASHINGTON · PI MORRISON, RICHARD S, MURPHY, SEAN PADRAIG · 2010 to 2014
$1.7M
NIA NIH HHS R01 AG033720NINDS NIH HHS R01 NS065319
6 · The paper itself

Abstract

Understanding how epigenetics influences the process and progress of a stroke could yield new targets and therapeutics for use in the clinic. Experimental evidence suggests that inhibitors of zinc-dependent histone deacetylases can protect neurons, axons, and associated glia from the devastating effects of oxygen and glucose deprivation. While the specific enzymes involved have yet to be clearly identified, there are hints from somewhat selective chemical inhibitors and also from the use of specific small hairpin RNAs to transiently knockdown protein expression. Neuroprotective mechanisms implicated thus far include the upregulation of extracellular glutamate clearance, inhibition of p53-mediated cell death, and maintenance of mitochondrial integrity. The histone deacetylases have distinct cellular and subcellular localizations, and discrete substrates. As a number of chemical inhibitors are already in clinical use for the treatment of cancer, repurposing for the stroke clinic should be expedited.

Indexed as

AxonsBrain IschemiaCell DeathHistone Deacetylase InhibitorsHumansNerve Fibers, MyelinatedNeuronsNeuroprotective AgentsStrokeHistone Deacetylase InhibitorsNeuroprotective Agents

Identifiers

PMID23881453
PMCPMC3805855
OpenAlexW2034722311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.